Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

PharmaCyte Biotech (PMCB) Return on Assets (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Return on Assets for 15 consecutive years, with 0.04% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Assets fell 10.0% to 0.04% in Q4 2025 year-over-year; TTM through Oct 2025 was 0.04%, a 10.0% decrease, with the full-year FY2025 number at 0.05%, down 10.0% from a year prior.
  • Return on Assets was 0.04% for Q4 2025 at PharmaCyte Biotech, up from 0.06% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.08% in Q1 2025 to a low of 0.54% in Q3 2021.
  • A 5-year average of 0.09% and a median of 0.05% in 2023 define the central range for Return on Assets.
  • Peak YoY movement for Return on Assets: skyrocketed 48bps in 2022, then decreased -12bps in 2025.
  • PharmaCyte Biotech's Return on Assets stood at 0.08% in 2021, then increased by 13bps to 0.07% in 2022, then skyrocketed by 47bps to 0.04% in 2023, then skyrocketed by 268bps to 0.06% in 2024, then tumbled by -171bps to 0.04% in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Return on Assets are 0.04% (Q4 2025), 0.06% (Q3 2025), and 0.06% (Q2 2025).